Panelists discuss how systemic therapy plays a crucial role in embolization-eligible hepatocellular carcinoma (HCC), ...

Hepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new cases and 830,200 deaths were registered in 2020, according to the World ...

Immunotherapy has revolutionised the treatment of advanced hepatocellular carcinoma, starting with atezolizumab–bevacizumab superseding sorafenib in the first line. But how have other areas of care ...

A research team led by Prof. SUN Cheng from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences, along with collaborators from the Agency for Science, ...

An expert discusses how, for advanced unresectable hepatocellular carcinoma (uHCC), clinicians monitor treatment efficacy ...

"The CARES-oo5 study showed a clinically meaningful and statistically significant improvement in the primary endpoint of PFS for unresectable HCC who received TACE plus immunotherapy-based ...

Previously-untreated patients with hepatocellular carcinoma (HCC), a common form of liver cancer, will have an immunotherapy-based treatment option after NICE gave the nod to NHS funding of Roche ...

laying the foundation for SPON2 + NK cell-targeted immunotherapy strategies. More information: Gengjie Jia et al, Spatial immune scoring system predicts hepatocellular carcinoma recurrence ...

Teclison, Inc., a clinical-stage oncology company dedicated to advancing immunotherapeutic treatments for solid tumors, today announced that Ray Lee, chief executive officer and co-founder of Teclison ...